Chronic medication intake in patients with stable coronary heart disease across Europe : evidence from the daily clinical practice : results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) registry by De Smedt, Delphine et al.
Journal Pre-proof
Chronic medication intake in patients with stable coronary heart
disease across Europe: Evidence from the daily clinical practice.
Results from the ESC EORP European Survey of Cardiovascular
Disease Prevention and Diabetes (EUROASPIRE IV) Registry
Delphine De Smedt, Tine De Backer, Mirko Petrovic, Guy De
Backer, David Wood, Kornelia Kotseva, Dirk De Bacquer
PII: S0167-5273(19)30566-2
DOI: https://doi.org/10.1016/j.ijcard.2019.09.015
Reference: IJCA 27990
To appear in: International Journal of Cardiology
Received date: 13 February 2019
Revised date: 21 August 2019
Accepted date: 5 September 2019
Please cite this article as: D. De Smedt, T. De Backer, M. Petrovic, et al., Chronic
medication intake in patients with stable coronary heart disease across Europe: Evidence
from the daily clinical practice. Results from the ESC EORP European Survey of
Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry,
International Journal of Cardiology(2019), https://doi.org/10.1016/j.ijcard.2019.09.015
This is a PDF file of an article that has undergone enhancements after acceptance, such
as the addition of a cover page and metadata, and formatting for readability, but it is
not yet the definitive version of record. This version will undergo additional copyediting,
typesetting and review before it is published in its final form, but we are providing this
version to give early visibility of the article. Please note that, during the production
process, errors may be discovered which could affect the content, and all legal disclaimers
that apply to the journal pertain.
© 2019 Published by Elsevier.
Jo
urn
al 
Pr
e-p
roo
f
Chronic medication intake in patients with stable coronary heart disease across Europe: evidence 
from the daily clinical practice. 
Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes 
(EUROASPIRE IV) Registry. 
Authors: Delphine De Smedt1, Tine De Backer2, Mirko Petrovic3, Guy De Backer4, David Wood5, 
Kornelia Kotseva6, Dirk De Bacquer7 
1 Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation 
2 Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Ghent 
University Hospital, Ghent, Belgium. This author takes responsibility for all aspects of the reliability 
and freedom from bias of the data presented and their discussed interpretation 
3 Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Ghent 
University Hospital, Ghent, Belgium. This author takes responsibility for all aspects of the reliability 
and freedom from bias of the data presented and their discussed interpretation 
4 Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation 
5 National Heart & Lung Institute, Imperial College London, London, UK. ESC fellow. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation 
6 National Heart & Lung Institute, Imperial College London, London, UK. ESC fellow. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation 
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
7 Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation 
Corresponding author: Delphine De Smedt, Ghent University, Corneel Heymanslaan 10, 9000 Gent, 
Belgium; delphine.desmedt@ugent.be 
Conflict of interest: The authors report no conflict of interest 
Acknowledgment & funding: This work was supported by AstraZeneca, Bristol Myers Squibb/Emea 
Sarl, GlaxoSmithKline, F Hoffman–La Roche (Gold Sponsors), Merck, Sharp & Dohme and Amgen 
(Bronze Sponsors) (unrestricted research grants to the European Society of Cardiology). 
The EUROASPIRE IV survey was carried out under the auspices of the European Society of Cardiology, 
EURObservational Research Programme. The sponsors of the EUROASPIRE surveys had no role in the 
design, data collection, data analysis, data interpretation, decision to publish, or writing the 
manuscript. The EUROASPIRE Study Group is grateful to the administrative staff, physicians, nurses 
and other personnel in the hospitals in which the survey was carried out and to all patients who 
participated in the surveys. EORP Oversight Committee, Executive Committee of the EURObservational 
Research Programme (EORP): Guy De Backer  BE  (Chair); Dirk De Bacquer,  BE; Stephan Gielen,  DE; Oliver 
Schnell,  DE; Jouko Sundvall,  FI;  Jaakko Tuomilehto,  FI; Philippe Amouyel,  FR; Kornelia Kotseva,  GB; David 
Wood,  GB; Aldo P. Maggioni,  IT; Lars Ryden,  SE . Steering Committee: Mirza Dilic, BA; Belma Pojskic, BA; Dusko 
Vulic, BA; Dirk De Bacquer, BE; Johan De Sutter, BE; Nina Gotcheva, BG; Evagoras Nicolaides, CY; Jan Bruthans, 
CZ; Renata Cifkova, CZ; Peter Heuschmann, DE; Stefan Stoerk, DE; Almudena Castro Conde, ES; Seppo Lehto, FI; 
Philippe Amouyel, FR; Kornelia Kotseva, GB; David Wood, GB; Ioannis Goudevenos, GR; Davor Milicic, HR; Zeljko 
Reiner, HR; Bela Merkely, HU; David Moore, IE; Diego Vanuzzo, IT; Kairat Davletov, KZ; Aleksandras Laucevicius, 
LT; Andrejs Erglis, LV; Jaap Deckers, NL; Monika Hollander, NL; Andrzej Pajak, PL; Ana Abreu, PT; Carlos Tavares 
Aguiar, PT; Dan Gaita, RO; Silvia Mancas, RO; Nebojsa Lalic, RS; Dragan Lovic, RS; Rafael Oganov, RU; Nana 
Pogosova, RU; Viveca Gyberg, SE; Martin Stagmo, SE; Zlatko Fras, SI; Lale Tokgozoglu, TR; Maryna Dolzhenko, UA. 
The registry was managed and organised by the EORP department including Myriam Glemot as Project 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
Officer, Marème Konte as Data Monitor. Overall activities were coordinated and supervised by Professor Aldo P. 
Maggioni (EORP Scientific Coordinator) and Thierry Ferreira (Head of EORP Department) 
Key words: coronary heart disease; EUROASPIRE; Medication 
  
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
Abstract 
Background: As advised by the European guidelines on cardiovascular prevention, medication intake 
is a major component of secondary prevention. The aim of this study is to provide an in-depth 
overview of the medication intake in stable European coronary heart disease (CHD) patients. 
Methods: Analyses are based on the EUROASPIRE IV survey, including CHD patients (18 to 80 years) 
who were hospitalized for a coronary event. These patients were interviewed and examined 6 
months to 3 years after their hospitalization. Information on cardiovascular medication intake is 
available for 7953 patients. 
Results: About 99.2% of patient were on any kind of cardiovascular medication and 67.6% of patients 
were taking at least 5 different cardiovascular drugs. Overall, even when patients are taking the 
recommended drug combination as advised by the European guidelines - accounting for their disease 
profile- a large proportion of patients is still not on blood pressure, LDL-C or HbA1c target. In 
addition, huge variations were seen in medication dose intake across countries. Comparing the dose 
intake to the defined daily dose (DDD as published by the WHO) indicated a substantial deviation 
from the DDDs for a large proportion of patients. 
Conclusion: This study provides a unique overview of the CVD medication intake in CHD patients. 
Overall, even when patients are taking the advised drug combination, a large proportion of patients 
is still not on risk factor target. Physicians should seek for a balance in medication intake and 
appropriate dose, accounting both for the benefits and risks of chronic drug intake. 
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INTRODUCTION 
 
Despite a steep decline in coronary heart disease (CHD) mortality in many countries, CHD remains the 
single most important cause of premature death worldwide and across Europe [1, 2]. Although 
mortality rates are decreasing, an increase in CHD prevalence is observed in the last decade, due to a 
rise in population size and age [2, 3]. Over 30 million persons in Europe are living with CHD [2]. In order 
to reduce this CHD burden, health care workers are advised to implement the European Guidelines on 
Cardiovascular Disease Prevention in daily clinical practice. These guidelines, developed by Joint 
European Societies task forces, aim to give directions to healthcare professionals in the treatment of 
their patients [4-6]. A focus is set on smoking cessation, healthy diet, physical activity, control of 
elevated blood pressure and cholesterol level in all patients and control of HbA1c in patients with 
diabetes, by adopting a healthy lifestyle and by prescribing appropriate medical treatment including 
pharmacological therapy. Especially in patients with established CHD, medication intake is a major 
component of their treatment strategy with a focus on lipid lowering, antihypertensive and antiplatelet 
medication [7]. Several studies have reported on cardiovascular drug intake in patients with 
cardiovascular disease such as the Prospective Urban Rural Epidemiological (PURE) study, the 
REduction of Atherothrombosis for Continued Health (REACH) study and the STabilization of 
Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) study, which show large 
variations over time and across geographical regions [8-10]. Most studies report on the intake of the 
different classes of CVD medication, but little is known about which particular drugs are being used 
(generic name), which dose is being taken, as well as which drug combinations are being prescribed. 
Hence, the aim of this study is to provide an in-depth overview of the medication intake in patients 
with stable CHD from across Europe based on data collected in a standardized manner, with an 
additional focus on CHD related comorbidities. To answer this research question, data from the 
EUROASPIRE IV survey are being used.  
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METHODS 
The EUROASPIRE IV survey has been described in more detail previously [11]. The EUROASPIRE surveys 
(since 1995) were initiated with the aim to assess how well the European Guidelines on cardiovascular 
disease prevention are being implemented in daily clinical practice [4-6]. Information from patients 
with CHD, men or women, aged ≥18 years and <80 years at the time of identification, who had been 
hospitalized for an acute myocardial infarction (AMI), an emergency or elective percutaneous coronary 
intervention (PCI), an emergency or elective coronary artery bypass graft (CABG) or acute myocardial 
ischaemia was collected. These patients were interviewed and examined 6 months to 3 years after the 
index hospitalization. Twenty-four European countries participated in the fourth survey in 2012-2013 
(Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Germany, 
Greece, Ireland, Latvia, Lithuania, the Netherlands, Poland, Romania, Russia, Serbia, Slovenia, Spain, 
Sweden, Turkey, Ukraine, and the UK). The participating countries represented one or more 
geographical areas with a defined population. In total, 74 centres were included. A sample of one or 
more hospitals within each geographical area was selected in such a way that any patients eligible for 
inclusion had an equal chance of being included in the survey. Local Research Ethics Committees 
approvals were obtained conform to the ethical guidelines of the 1975 Declaration of Helsinki. Written, 
informed consent was obtained from each participant by the investigator by a signed declaration.  
Information on patient demographics, medical history, risk factor behaviour, risk factor awareness, 
lifestyle changes as well as advise received, were collected by centrally trained research staff using a 
structured questionnaire, standardised methods and instruments, and central laboratory 
measurements. In addition, medication intake, both generic name and total daily dose were available. 
Furthermore, physical measures including height and weight (to derive body mass index (BMI)), blood 
pressure (measured twice) and breath carbon monoxide (to validate self-reported smoking status) 
were performed and a blood sample was taken. Glycated haemoglobin (HbA1c) was measured and 
LDL-cholesterol (LDL-C) was estimated according to the Friedewald’s formula. The glomerular filtration 
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rate (eGFR) was estimated from serum creatinine by means of the Chronic Kidney Disease 
Epidemiology Collaboration equation [12].  
Patient characteristics 
Education level is divided in three categories: primary education (primary school or less), secondary 
education (secondary school completed, high school completed or intermediate between secondary 
level completed), and high education (university/college degree or equivalent). Smoking at the time of 
interview is defined as self-reported smoking, and/or a breath carbon monoxide exceeding 10 ppm. 
Obesity is defined as a BMI ≥30kg/m². Blood pressure, LDL-C and HbA1C values were evaluated against 
the guidelines that were in place during the EUROASPIRE IV survey (European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2012))[5]). An elevated LDL-C was 
defined as an LDL-C ≥2.5mmol/L and a more stringent threshold with an LDL-C ≥1.8mmol/L was also 
used. An elevated blood pressure was defined as SBP/DBP ≥140/90mmHg (SBP/DBP ≥140/80mmHg in 
patients with diabetes). Finally, an elevated HbA1c was defined as HbA1c ≥7%.   
Comorbidities 
Comorbidities including stroke, peripheral artery disease and heart failure were defined as ever being 
hospitalized for one of these illnesses respectively. Chronic kidney disease (CKD) was defined as eGFR 
<60 ml/min/1.73m² based on the serum creatinine in the blood sample. Diabetes was defined as self-
reported diabetes by the patient.  
 
Medication intake 
Information on cardiovascular medication intake includes the use of  aspirin or other antiplatelet drugs, 
anti-coagulants, beta-blockers, angiotensin-converting-enzyme inhibitors (ACE-I), angiotensin II 
receptor blockers (ARBs), renin inhibitors, calcium channel blockers, diuretics, other anti-hypertensive 
drugs, nitrates, If channel inhibitor, potassium channel activators (vasodilator), other anti-angina 
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drugs, metabolic agents, digitalis glycosides, anti-arrhythmic drugs, statins, fibrates, nicotinic acid 
group, cholesterol absorption inhibitors, resins, omega-3 fatty acids, insulin, oral sulphonylurea, oral 
non sulphonylurea, metformin, and alpha glucosidase inhibitors. Generic name and the total daily dose 
for each drug was recorded. Furthermore, patients provided information about the intake of hormone 
replacement therapy, appetite suppressants/other antiobesity drugs, nicotine replacement therapy, 
bupropion, varenicline, antidepressants, and antianxiety medication. To assess medication adherence, 
patients were asked whether they have missed doses of the prescribed medication since the recruiting 
coronary event, and how often they took their medications as prescribed by their physician in the past 
month. 
Analyses 
Descriptive statistics were used to estimate the medication intake, stratified by gender and age class. 
To analyse dose intake, the defined daily dose (DDD) was used according to the DDD index 2019 
published by the WHO [13]. Patients taking a daily dose between 75% and 125% of the DDD were 
considered to be on the DDD. In addition, the recommended drug combination for specific patient 
profiles (CHD comorbidities) was described. Data were analysed with IBM SPSS 24. 
RESULTS 
A total of 7,998 patients with coronary heart disease were interviewed (participation rate 48.7%). 
Information on medication intake was available for 95.7% (7653 individuals) of patients. The median 
time between index event and interview was 1.35 years (IQR= 0.95-1.93). 
An overview of the patient characteristics is provided in Table 1. A majority (75.7%) were men, and the 
mean age was 64 years (SD=9.6). 17.4% of patients were primary educated and 22.4% had a high 
education. 16.0% of patients were active smokers at the time of the interview (of which 6.1% had a CO 
value >10 ppm although reporting in the interview to be a non-smoker), 37.6% were obese, 42.8% had 
an elevated blood pressure, 42.0% had an LDL-C ≥2.5mmol/L and 80.5% had an LDL-C ≥1.8mmol/L . In 
patients with diabetes, 47.4% had an HbA1c ≥7%. Comorbidities were present in 45.2% of patients. 
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99.2% of patients were on any kind of cardiovascular medication as defined in the method section, 
with 67.6% of patients taking at least 5 different kinds of cardiovascular drugs. Antiplatelet intake was 
seen in 93.8% of patients, with the largest proportion seen in younger patients (<65 years) and men. 
6.5% of patients were taking anticoagulants with a larger intake seen in older patients (≥65 years). 
Beta-blocker intake was reported in 82.6% of patients, 58.1% was taking ACE-I (largest intake is seen 
in males) and 17.1% was taking ARBs (larger intake in older patients (≥65 years) and women). Diuretics 
were taken by 29.8% of patients, and statins by 85.7%. In addition, 22.5% was taking calcium channel 
blockers and 23.9% was taking nitrates. In patients with diabetes, 83.7% was on any kind of 
antidiabetica, with 56.9% taking metformin, 24.9% taking oral sulphonylurea, 11.7% taking oral non-
sulfonylurea and with 27.1% using insulin (Table 2). Large variations were seen between geographical 
areas (appendix). Intraclass correlation (ICC) for medication intake across countries ranged between 
4% and 63%. Even on a more aggregated level (Northern, Southern, Western, Eastern Europe) 
differences in treatment were observed (Appendix 2 and 3). In addition to the drug class, information 
on the generic name and the medication dose is provided in Table 3. Large variations were seen in 
medication dose intake, ranging from 0.5% of patients taking the DDD to 98.6% of patient taking the 
DDD. An overview of the recommended pharmacotherapy per patients’ comorbidity profile is given in 
Table 4. Among patients without comorbidities, 79.4% of them is taking an antiplatelet, an 
antihypertensive and a statin. Overall, even when patients are on the recommended treatment a large 
proportion of patients is still not on blood pressure, LDL-C or HbA1c target. 
About 66.0% of patients never missed taking the prescribed medication dosage, and 74.2% indicated 
to take the medication as prescribed by their physician during the past month. 
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DISCUSSION 
The European guidelines on cardiovascular disease prevention focus on the optimal management of 
CVD risk factors. Medication intake is an important cornerstone of cardiovascular therapy, especially 
in patients with established CVD [4-6].  
Previous research 
Several studies have reported on medication intake in CVD patients previously, with large variations 
between regions and over time. The PURE (Prospective Urban Rural Epidemiological) study, conducted 
between 2005 and 2009 in high income countries, reported an antiplatelet intake of 64.1%, a beta-
blocker intake of 46.5%, an angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor 
blockers (ARB) intake of 51.7% and a statin intake of 70.9% in patients with a history of CHD or stroke 
[10]. Baseline results from the STABILITY (STabilization of Atherosclerotic plaque By Initiation of 
darapLadIb TherapY) trial (2010) in chronic CHD patients from 39 countries across the world showed 
that 96% of patients were on antiplatelets, 79% on beta-blockers, 77% on ACE-I/ARB and 97% on 
statins [9]. The National Health and Nutrition Examination Survey in the US (2007-2010) reported a 
beta blocker intake of 55%, ACE-I/ARB intake of 45% and lipid lowering agent intake of 62% among 
CHD patients [14]. Within the REACH (REduction of Atherothrombosis for Continued Health) registry, 
including patients with atherothrombosis, 82% were on antiplatelet therapy, 57% on a beta-blocker, 
65% on an ACE-I/ARB, and 83% on lipid-lowering therapy [8]. Time-trend analyses based on the 
EUROASPIRE surveys (EUROASPIRE II in 2000 - EUROASPIRE IV in 2013) have shown an increased 
cardiovascular medication intake of antiplatelet therapy (85.2% to 94.8%), beta-blockers (62.6% to 
80.6%), angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (42.3% to 70.7%) 
and statins (55.2% to 88.6%) [11].  
EUROASPIRE findings 
The current study adds to this knowledge by providing an in-depth overview of the medication intake 
in patients with stable CHD across Europe with an additional focus on comorbidities using data from 
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the EUROASPIRE IV survey. In addition to the frequently prescribed drug classes like antiplatelet, 
statins, ACE-I/ARBs and beta blockers, information was given on less prevalent drug classes. Overall, 
nearly all patients are on any kind of cardiovascular medication. Overall, about 63.6% of patients was 
taking at least an antiplatelet, a statin, and an antihypertensive drug. Large variations are seen across 
regions, which is in line with the EUROSTAT findings on prescribed drug intake and is likely to be caused 
by country specific guidelines recommendations and habits, differences in health care system as well 
as the differences in medical education [15]. Looking at comorbidities like heart failure, PAD, stroke, 
CKD and diabetes showed that no more than half of patients was taking the recommended drug 
combinations. Furthermore, substantial variations were seen in the drug doses. According to Halvorsen 
et al (2016), many CHD patients were not optimally treated, because of under-prescription, reduced 
adherence, or under-dosing of medication [16]. The mean doses reported by the EUROASPIRE patient 
were very similar to those reported by Halvorsen et al, 12-18 months after their index event [16]. 
Dosage 
There are several possible explanations for patients not being on the WHO DDD. First of all the WHO 
DDD often differ from the CVD guideline recommended dosages. The recommended dose is however 
difficult to define and should be based on clinical trial results [17].  Patients or their treating physician 
can have several reasons to deviate from the recommended drug dose. Vanderlaan et al (2017), 
discussed the medication-related burden of chronic cardiovascular medication use. Several patients 
were concerned about the side-effects or the long term effects of chronic medication intake. Chronic 
medication intake could affect their social and daily life and could have a negative impact on a person’s 
quality of life [18]. A recent review by Albarqouni et al (2017), suggested that many patients expect a 
substantial risk reduction or prolongation in life in order to take cardiovascular medication, although 
patients with a history of CVD were more willing to take the prescribed medication compared to non 
CVD patients [19]. Nevertheless, Trewby et al (2002) reported that about 10% of coronary patients 
were not willing to take the prescribed drug at hospital discharge [20]. In addition to this, some patients 
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suffered from side effects, making them to quit a given medication either in consultation with their 
physician or on their own initiative. This was confirmed by Arnold et al. (2013), who discussed that 
some patients  were on a lower dose than the recommended dose because of side-effects. Others 
were not uptitrated appropriately after discharge due to miscommunication with the treating 
physician or unawareness of the indicated dose. Furthermore, some patients were taking a 
combination of drugs within a given drug class, e.g. a combination of different antihypertensive drugs 
at lower dose in order to avoid side-effects of one single drug at a higher dose. Hence, when adding 
the associated doses of the combination therapy these patients a were often on target with the 
recommended drug dose [17]. Furthermore, while there is overwhelming evidence of the benefit of 
taking antiplatelets, statins, ACE-I/ARB and beta blockers shortly after a coronary event, less is known 
about the long term benefits and risks of taking cardiovascular medication [21]. Especially in older 
patients with multimorbidity and changes in pharmacodynamics and pharmacokinetics, polypharmacy 
and the associated drug-disease and drug-drug interactions are of concern [21, 22]. As reported by 
Rossello et al, the decision to prescribe a drug, is often based on the presence of a single emerging 
disease taking into account the associated guidelines for that illness, while in reality clinicians should 
apply a more holistic approach, considering the complete disease profile of a patient, including 
comorbidities and other risk factors. Polypharmacy has a major impact both on the health care system, 
by increasing the financial pressure as well as on the patient by causing possible adverse events, and 
complications [20]. A balance in appropriate medication use should be searched for, in order for the 
patient to benefit from the prescribed drug combinations as much as possible, without suffering from 
the side effects associated with polypharmacy [21]. Indeed, polypharmacy is common in CHD patients, 
with about 67.6% of the EUROASPIRE patients taking at least 5 different CVD medications. A possible 
solution to increase adherence rates and reduce side effects is the use of fixed dose combination pills 
(also called single pill combinations –SPC) or polypills [23]. 18.3% of the EUROASPIRE patients indicated 
to take a combination of different drugs in one tablet. 
.  
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Limitations 
Although this study gives a unique overview of the drug treatment in European patients with stable 
coronary disease using a standardized data collection approach, caution is needed when interpreting 
the present study results. Participants were selected from predefined geographical areas, and might 
not be representative for the country included in the study. Possible selection bias exists, since a 
variety of hospital centres with different interview rates were included (both university and non-
university hospitals, rural and urban hospitals). Some hospitals did not provide all interventional 
services, furthermore a difference in disease severity and patient characteristics between hospitals 
was observed, influencing the medication intake. On the other hand, including various kinds of hospital 
centres, allowed us to include a wide range of patient profiles, and reduced the risk of selecting a 
particular patient group. The reported drug intake was limited to cardiovascular medications, hence 
we have no information on other drug intake. Only comorbidities such as stroke, heart failure, PAD, 
CKD and diabetes were recorded, while CHD patients might suffer from a various range of other 
comorbidities. The use of WHO DDDs does not allow us to conclude about over- or underdosing, since 
these DDD often differ from the guideline recommended CVD dose. In addition, medication intake as 
well as medication adherence might change in function of time. Since the time between index event 
and interview varied between 6 months and 3 years, this might have influenced the prescribed drug 
treatment. And finally, this study gives a view of the medication intake during 2012-2013, meanwhile 
other CVD drugs entered the market such as PCSK9 inhibitors and new antidiabetic agents, for which 
no information was available in this study. Hence medication intake as presented in this paper might 
not completely reflect medication intake management nowadays. The recently performed 
EUROASPIRE V survey will add to this knowledge and will allow to investigate how medication 
management has changed over time. Future studies should also focus on how medication intake, drug 
dose and medication adherence is associated with achieving the risk factor targets. 
Conclusion 
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In conclusion, this study provided a unique overview of CVD medication intake in stable CHD patients. 
Despite the use of cardiovascular drugs, a large proportion of patients was still not on blood pressure 
and LDL-C target. Large variations were seen in drug dose intake. In patients with comorbidities, the 
recommended medication intake was often not achieved. Physicians should seek for a benefit-risk 
balance in prescribing medication, taking into consideration advantages and disadvantages of chronic 
drug intake. 
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Table 1: Patient characteristics (%/N) 
Men 75.7% (6017/7953) 
Age (Mean (SD)) 64.0 (9.6) 
Age class  
<65 years  51.5% (4099/7953) 
≥65 years 48.5% (3854/7953) 
Educational level  
Primary 17.4% (1371/7895) 
Secondary 60.3% (4759/7895) 
High 22.4% (1765/7895) 
Recruiting diagnosis  
CABG 12.8% (1020/7953) 
PCI 54.1% (4306/7953) 
MI 22.7% (1805/7953) 
Ischaemia 10.3% (822/7953) 
Smoking  16.0% (1273/7953) 
Obesity (≥30kg/m²) 37.6% (2975/7920) 
Diabetes 26.8% (2122/7915) 
Stroke 4.3% (337/7797) 
Peripheral artery disease 3.7% (291/7762) 
Heart failure 4.5% (344/7715) 
Chronic kidney disease 17.7% (1323/7462) 
Elevated blood pressure (≥140/90mmHg and ≥140/80mmHg if diabetes) 42.8% (3381/7903) 
Elevated LDL (≥2.5mmol/L) 42.0% (3021/7199) 
Elevated LDL (≥1.8mmol/L) 80.5% (5796/7199) 
Elevated HbA1c* (≥7%) 47.4% (941/1985) 
* in patients with diabetes 
Targets based on the European Guidelines on cardiovascular disease prevention in clinical practice (5th joint task force) 
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Table 2: Medication intake in CHD patients 
 Men Women All (n=7953) 
<65 years (n=2393) ≥65 years (n=2724) <65 years (n=806) ≥65 years (n=1130) 
ANTITHROMBOTIC AGENTS 
Anti-platelets 96% 92.2% 94.7% 90.7% 93.8% 
Anticoagulants  3.9% 9.7% 3.3% 8.4% 6.5% 
BETA BLOCKING AGENTS 
Beta-blocker 84.2% 80.7% 82.1% 82.8% 82.6% 
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 
ACE inhibitors 63.2% 57.2% 54.2% 54.2% 58.9% 
ARBs 13.4% 18.3% 17.5% 24.5% 17.1% 
Renin inhibitors 0.1% 0.1% 0.2% 0.1% 0.1% 
CALCIUM CHANNEL BLOCKERS 
Calcium-channel blockers 17.6% 24.9% 22.7% 31.2% 22.5% 
DIURETICS 
Diuretics 22.5% 34.9% 28% 39.7% 29.8% 
OTHER ANTIHYPERTENSIVE AGENTS 
Other anti-hypertensives 2.2% 4.1% 2.5% 3.2% 3.0% 
CARDIAC THERAPY      
Anti-arrhythmics 2.7% 3.9% 2% 4% 3.2% 
Digitalis glycosides 0.9% 2.2% 1.2% 2.3% 1.6% 
Nitrates 21.3% 25.1% 24.9% 28.1% 23.9% 
If inhibitors 2.6% 1.6% 3.6% 2.2% 2.3% 
Potassium channel activators 0.8% 0.9% 1.4% 0.7% 0.9% 
Other anti-anginals 0.8% 1.3% 2% 1.4% 1.2% 
Metabolic agents 5.5% 6.8% 7.1% 8.6% 6.5% 
LIPID MODIFYING AGENTS 
Statins 86.9% 85.7% 82.4% 84.3% 85.7% 
Fibrates 2.2% 1.1% 2.9% 1.3% 1.8% 
Nicotinic acid 0.1% 0% 0.4% 0% 0.1% 
Cholesterol absorption inhibitors 3.2% 3.1% 2.5% 3% 3.1% 
Resins 0% 0.1% 0% 0% 0.1% 
Omega-3 fatty acids 6% 3.6% 4.8% 5% 4.9% 
ANTI-DIABETIC AGENTS*  (n=747) (n=795) (n=225) (n=355) (n=2122) 
Insulin 26.1% 25.0% 35.6% 28.5% 27.1% 
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Oral Sulphonylurea 24.4% 26.2% 24.4% 23.4% 24.9% 
Oral non-sulphonylurea 11.0% 13.2% 10.7% 10.7% 11.7% 
Metformin 61.6% 55.1% 55.6% 52.1% 56.9% 
Alpha-glucosidase inhibitors 0.5% 0.8% 1.8% 1.7% 0.9% 
* in patients with diabetes 
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Table 3: Dose intake (if >2.5% of patients are taking the drug) 
 All (% (n)) DDD % on DDD % below DDD % above DDD Mean dose (mg) 
ANTITHROMBOTIC AGENTS  
Acetylsalicyclic acid 90.1% (7126/7911) 1 tablet NA NA NA 96.1 (34.0) 
Clopidogrel 38.1% (3010/7911) 75 mg 98.7% 0% 1.3% 76.5 (10.2) 
Warfarin sodium 3.8% (299/7911) 7.5mg 11.5% 86.9% 1.6% 4.4 (1.6) 
BETA BLOCKING AGENTS  
Bisoprolol 35.9% (2841/7911) 10 mg 12.8% 86.9% 0.3% 4.4 (2.8) 
Metoprolol 31.1% (2458/7911) 150mg 2.5% 92.7% 4.8% 69.0 (41.5) 
Nebivilol 6.2% (494/7911) 5mg 74.2% 25.6% 5.2% 4.5 (1.6) 
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM  
Ramipril 26.6% (2105/7911) 2.5mg 30.3% 8.9% 60.8% 5.2 (4.2) 
Perindopril 16.3% (1290/7911) 4mg 49% 20.4% 30.6% 5.8 (3.3) 
Enalapril 6.9% (546/7911) 10mg 33.7% 22.3% 44% 14.6 (9.2) 
Lisinopril 4.1% (325/7911) 10mg 29.3% 31.7% 39% 13.2 (9.3) 
Losartan 4.7% (375/7911) 50mg 50.7% 17.3% 32% 60.7 (28.5) 
Valsartan 4.6% (362/7911) 80mg 26.8% 7.1% 66.1% 152.6 (79.3) 
Candesartan 3.4% (272/7911) 8mg 30% 13.6% 56.4% 14.2 (8.5) 
CALCIUM CHANNEL BLOCKERS  
Amlodipin 15.4% (1216/7911) 5mg 48.9% 2.1% 39% 7.0 (2.8) 
Lercanidipine 2.6% (204/7911) 10mg 58.9% 8.1% 33% 12.9 (5.5) 
DIURETICS  
Hydrochlorothiazide 8.9% (701/7911) 25mg 31.9% 63.6% 4.5% 17.6 (8.6) 
Indapamide 4.8% (378/7911) 2.5mg 21.3% 77.3% 1.4% 1.8 (1.6) 
Furosemide 9.7% (770/7911) 40mg 57.5% 28.7% 13.8% 45.6 (46.3) 
Torasemide 3.5% (274/7911) 15mg 2.7% 77.6% 19.7% 16.4 (27.0) 
Spironolactone 7.1% (562/7911) 75mg 0.5% 98% 1.5% 29.1 (12.9) 
CARDIAC THERAPY       
Amiodarone 2.7% (217/7911) 200mg 80.3% 15% 4.7% 197.0 (76.0) 
Isosorbide mononitrate 10.2% (810/7911) 40mg 42% 27.9% 30.1% 44.6 (23.1) 
Isosorbide dinitrate 4.5% (354/7911) 60mg 8.6% 89.8% 1.6% 31.7 (20.4) 
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GNT spray 8% (631/7911) 2.5mg NA NA NA  
Trimetazidine 5.8% (456/7911) 40mg 12.7% 2.3% 85% 62.9 (13.0) 
LIPID MODIFYING AGENTS  
Atorvastatin 46.8% (3700/7911) 20mg 37.8% 13.2% 49% 33.2 (20.5) 
Rosuvastatin 15.8% (1249/7911) 10mg 41.9% 6.3% 51.8% 16.5 (8.7) 
Simvastatin 20.4% (1611/7911) 30mg 0.9% 37.4% 61.7% 32.8 (12.9) 
Ezetimibe 3.1% (244/7911) 10mg 99.2% 0.4% 0.4% 10.0 (0.7) 
Omacor 3% (234/7911)  NA NA NA  
ANTI-DIABETIC AGENTS*       
Short-acting insulin 13.5% (286/2120) 40U 38.8% 39.4% 21.8% 42.0 (31.7) 
Intermediate insulin 4.8% (102/2120)  NA NA NA  
Long-acting insulin 16.3% (345/2120) 40U 31.4% 50.7% 17.9% 39.2 (35.4) 
Glibenclamide 2.5% (53/2120) 10mg 22.2% 72.2% 5.6% 6.5 (3.5) 
Glimepiride 9.3% (198/2120) 2mg 32.6% 9.6% 57.8% 3.4 (4.4) 
Gliclazide 10.7% (226/2120) 60mg 39% 32.2% 28.8% 78.4 (87.6) 
Sitagliptin 5.9% (124/2120) 100mg 79.5% 19.7% 0.8% 92.8 (21.3) 
Repaglinide  2.9% (62/2120) 4mg 19% 44.4% 36.5% 3.6 (2.6) 
Metformin  57% (1208/2120) 2000mg 43.3% 45.4% 11.3% 1483.3 (680.4) 
* in patients with diabetes 
DDD: defined daily dose 
On DDD: 75%-125% of DDD; below DDD: <75% of DDD; above DDD: >125% of DDD 
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Table 4: Recommended therapy according to patient profiles 
 If on treatment 
 on treatment BP<140/90mmHg (140/80mmHg if diabetes) LDL<2.5mmol/L LDL<1.8mmol/L HbA1c<7% 
CHD (n=4083)      
Antiplatelet + statin + ACE/ARB  62.2% 64.6% 60.3% 17.9% NA 
Antiplatelet + statin + BB  69.8% 67.7% 59.2% 17.5% NA 
Antiplatelet + statin + diuretic  16.6% 62.1% 55.6% 15.6% NA 
Antiplatelet + statin +  79.4% 66.7% 59.9% 17.8% NA 
CHD & HF (n=112)      
Antiplatelet + statin + ACE/ARB 56.3% 67.7% 54.1% 14.8% NA 
Antiplatelet + statin + ACE/ARB + beta-blocker 49.1% 70.4% 54.7% 15.1% NA 
Antiplatelet + statin + ACE/ARB + beta-blocker + 
diuretic 
16.1% 77.8% 58.8% 5.9% NA 
CHD & PAD (n=91)      
Antiplatelet + statin + ACE  56.0% 66.7% 70.8% 16.7% NA 
Antiplatelet + statin + ACE + beta-blocker 51.6% 68.1% 70.5% 11.4% NA 
CHD & stroke (n=120)      
Antiplatelet/anticoagulant +  Statin + ACE 48.3% 69.0% 63.2% 14.0% NA 
CHD & CKD (n=672)      
Antiplatelet + statin + ACE/ARB 60.1% 58.9% 62.5% 20.5% NA 
Journal Pre-proof
Jou
rna
l Pr
e-p
roo
f
CHD & diabetes (n=1262)      
Statin + metformin 57.8% 35.5% 73.7% 33.5% 55.2% 
Statin + metformin + ACE/ARB  47.1% 33.5% 74.2% 34.2% 54.1% 
Statin + metformin + ACE/ARB + 
antiplatelet/anticoagulant  
46.7% 33.6% 74.3% 34.5% 54.0% 
CHD & HF & diabetes (n=55)      
Statins + ACE/ARB + antidiabetic 47.3% 61.5% 64.0% 24.0% 50.0% 
Statins + ACE/ARB + antidiabetic + beta-blocker  41.8% 65.2% 63.6% 27.3% 47.8% 
Statins + ACE/ARB + antidiabetic + beta-blocker + 
diuretic 
29.1% 68.8% 62.5% 25.0% 56.3% 
CHD & PAD & diabetes (n=54)      
Antiplatelet + statin + ACE + antidiabetic 35.2% 21.1% 75.0% 31.3% 52.6% 
Antiplatelet + statin + ACE + antidiabetic + beta-
blocker  
27.8% 26.7% 71.4% 35.7% 53.3% 
CHD & stroke & diabetes (n=66)      
Antiplatelet/anticoagulant + statin + ACE + 
antidiabetic 
40.9% 33.3% 79.2% 45.8% 40.7% 
CHD & CKD & diabetes (n=313)      
Antiplatelet + statin + ACE/ARB +antidiabetic 50.5% 42.4% 70.5% 32.9% 45.6% 
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HIGHLIGHTS 
 Nearly all stable coronary patients are on some kind of cardiovascular drug 
 Despite the use of cardiovascular drugs, a large proportion of patients is still not on risk 
factor target 
 In patients with comorbidities, the recommended medication uptake is often not achieved 
 Physicians should seek for a benefit-risk balance in prescribing medication 
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